![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Université de Sherbrooke in Canada will test if LYSOVETA, Aker BioMarine’s new delivery platform based on LPC-bound EPA/DHA from krill, is more effective in increasing the concentration of DHA in the brain and improving cognition.
Lead Product(s): Icosapent Ethyl,DHA
Therapeutic Area: Neurology Product Name: Lysoveta
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Université de Sherbrooke Department of Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 15, 2021